Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Colorectal Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 24 articles: HTML format Text format

Single Articles

June 2019
1. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
   Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
   J Clin Oncol. 2019 Jun 10:JCO1802059. doi: 10.1200/JCO.18.02059.
   PubMed     Text format     Abstract available
   
   
   
2. STEBBING J, Singh Wasan H
   Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making.
   J Clin Oncol. 2019 Jun 7:JCO1901185. doi: 10.1200/JCO.19.01185.
   PubMed     Text format    
   
   
   May 2019
3. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
   Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
   J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
   PubMed     Text format     Abstract available
   
   
   
4. LENZ HJ, Ou FS, Venook AP, Hochster HS, et al
   Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
   J Clin Oncol. 2019 May 1:JCO1802258. doi: 10.1200/JCO.18.02258.
   PubMed     Text format     Abstract available
   
   
   April 2019
5. LIEU C, Kennedy EB, Bergsland E, Berlin J, et al
   Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
   J Clin Oncol. 2019 Apr 15:JCO1900281. doi: 10.1200/JCO.19.00281.
   PubMed     Text format     Abstract available
   
   
   March 2019
6. VAN CUTSEM E, Huijberts S, Grothey A, Yaeger R, et al
   Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
   J Clin Oncol. 2019 Mar 20:JCO1802459. doi: 10.1200/JCO.18.02459.
   PubMed     Text format     Abstract available
   
   
   
7. INNOCENTI F, Ou FS, Qu X, Zemla TJ, et al
   Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
   J Clin Oncol. 2019 Mar 13:JCO1801798. doi: 10.1200/JCO.18.01798.
   PubMed     Text format     Abstract available
   
   
   November 2018
8. MODEST DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, et al
   Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
   J Clin Oncol. 2018 Nov 2:JCO1800052. doi: 10.1200/JCO.18.00052.
   PubMed     Text format     Abstract available
   
   
   October 2018
9. GUINTER MA, McCullough ML, Gapstur SM, Campbell PT, et al
   Associations of Pre- and Postdiagnosis Diet Quality With Risk of Mortality Among Men and Women With Colorectal Cancer.
   J Clin Oncol. 2018 Oct 19:JCO1800714. doi: 10.1200/JCO.18.00714.
   PubMed     Text format     Abstract available
   
   
   September 2018
10. QIN S, Li J, Wang L, Xu J, et al
    Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
    J Clin Oncol. 2018 Sep 10:JCO2018783183. doi: 10.1200/JCO.2018.78.3183.
    PubMed     Text format     Abstract available
    
    
    June 2018
11. MO M, Yang J, Zhu X, Zhu J, et al
    Bevacizumab Maintenance in Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jun 4:JCO2018783795. doi: 10.1200/JCO.2018.78.3795.
    PubMed     Text format    
    
    
    May 2018
12. VAN DIJK E, Biesma HD, Cordes M, Smeets D, et al
    Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
    J Clin Oncol. 2018 May 24:JCO2017771782. doi: 10.1200/JCO.2017.77.1782.
    PubMed     Text format     Abstract available
    
    
    April 2018
13. VENOOK AP
    Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
    J Clin Oncol. 2018 Apr 5:JCO2018778423. doi: 10.1200/JCO.2018.77.8423.
    PubMed     Text format    
    
    
    
14. ANDRE T, Vernerey D, Mineur L, Bennouna J, et al
    3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017760355. doi: 10.1200/JCO.2017.76.0355.
    PubMed     Text format     Abstract available
    
    
    
15. SOBRERO A, Lonardi S, Rosati G, Di Bartolomeo M, et al
    FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017762187. doi: 10.1200/JCO.2017.76.2187.
    PubMed     Text format     Abstract available
    
    
    March 2018
16. SUN R, Horiguchi M, Wei LJ
    Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
    J Clin Oncol. 2018 Mar 20:JCO2017775643. doi: 10.1200/JCO.2017.77.5643.
    PubMed     Text format    
    
    
    February 2018
17. FADELU T, Zhang S, Niedzwiecki D, Ye X, et al
    Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    J Clin Oncol. 2018 Feb 28:JCO2017755413. doi: 10.1200/JCO.2017.75.5413.
    PubMed     Text format     Abstract available
    
    
    January 2018
18. OVERMAN MJ, Lonardi S, Wong KYM, Lenz HJ, et al
    Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jan 20:JCO2017769901. doi: 10.1200/JCO.2017.76.9901.
    PubMed     Text format     Abstract available
    
    
    
19. APARICIO T, Ghiringhelli F, Boige V, Le Malicot K, et al
    Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
    J Clin Oncol. 2018 Jan 18:JCO2017752931. doi: 10.1200/JCO.2017.75.2931.
    PubMed     Text format     Abstract available
    
    
    
20. KENZIK KM, Balentine C, Richman J, Kilgore M, et al
    New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
    J Clin Oncol. 2018 Jan 16:JCO2017749739. doi: 10.1200/JCO.2017.74.9739.
    PubMed     Text format     Abstract available
    
    
    December 2017
21. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Text format     Abstract available
    
    
    
22. XU J, Kim TW, Shen L, Sriuranpong V, et al
    Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    J Clin Oncol. 2017 Dec 7:JCO2017743245. doi: 10.1200/JCO.2017.74.3245.
    PubMed     Text format     Abstract available
    
    
    November 2017
23. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Text format     Abstract available
    
    
    February 2017
24. LOBERG M, Holme O, Kalager M
    Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.
    J Clin Oncol. 2017;35:568-569.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: